Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHPS | P49366 | 8/20 | 0.46 |
| ▸ | EDNRA | P25101 | 5/20 | 0.41 |
| ▸ | EDNRB | P24530 | 4/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | AHR | P35869 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064360 | 0.87 | DHPS (0.47) | DHPSEDNRAEDNRBIKBKBNPC1 | |
| SCHEMBL4061152 | 0.86 | EDNRB (0.45) | EDNRAEDNRB | |
| SCHEMBL4060142 | 0.84 | DHPS (0.54) | DHPSEDNRAEDNRBMEN1ALDH1A1 | |
| SCHEMBL5765220 | 0.83 | DHPS (0.40) | DHPSEDNRAIKBKBPARP1RAB9A | |
| SCHEMBL5761894 | 0.80 | IKBKB (0.41) | DHPSMKNK2MKNK1IKBKBPARP1 | |
| SCHEMBL7700001 | 0.80 | MYC (0.48) | DHPSPARP1MEN1ALDH1A1POLB | |
| SCHEMBL7700540 | 0.76 | EDNRB (0.38) | DHPSEDNRAEDNRB | |
| SCHEMBL5632892 | 0.75 | EDNRB (0.42) | EDNRAEDNRB | |
| SCHEMBL4061140 | 0.74 | EDNRA (0.67) | DHPSEDNRAEDNRBABCC3ABCC4 | |
| SCHEMBL5764477 | 0.73 | PIK3CA (0.46) | MAPTSMN1; SMN2MEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7091201-B2 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-15 | — | — | US | disclosed |
| EP-1309564-B1 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-14 | — | — | EP | disclosed |
| US-6951856-B2 | Arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2005-10-04 | — | — | US | disclosed |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-05-27 | — | — | US | disclosed |
| US-20030220359-A1 | Novel arylethene-sulfonamides | ACTELION PHARMACEUTICALS LTD. (CH) | 2003-11-27 | — | — | US | disclosed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | disclosed |
| EP-1309564-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
| WO-2002008200-A2 | ARYLETHENE-SULFONAMIDES, THEIR PREPARATION AND THEIR USE AS ENDOTHELIN ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220359-A1 | Novel arylethene-sulfonamides | EDNRA, ECE2, ECE1 | DHPS 424/4885EDNRA 1/4885EDNRB 4/4885 |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | EDNRA, EDNRB, ECE2 | DHPS 1235/4885EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.